SEC Filing Form 4 for BIOLIFE SOLUTIONS INC

This filing details stock transactions by Sean Werner, Chief Technology Officer of BIOLIFE SOLUTIONS INC, on October 6, 2026. Werner acquired 45,838 shares and 48,232 shares of common stock through vesting of restricted stock awards, as per footnotes F2 and F3. These awards vested based on the company's total shareholder return performance. Subsequently, Werner disposed of 71,226 shares in connection with tax withholdings (footnote F4) and another 69,979 shares as part of a merger agreement (footnote F1). The merger involved Bravo Merger Sub I, Inc. acquiring the company, with shareholders receiving $11.25 in cash and 0.1442 shares of Repligen common stock per share. Following these transactions, Werner holds 0 shares directly.